B-type natriuretic peptide in lymphedema.
Identifieur interne : 002571 ( PubMed/Checkpoint ); précédent : 002570; suivant : 002572B-type natriuretic peptide in lymphedema.
Auteurs : J. Todd [Royaume-Uni] ; T. Austwick ; D. Berridge ; L B Tan ; J H BarthSource :
- Lymphology [ 0024-7766 ] ; 2011.
Descripteurs français
- KwdFr :
- MESH :
- diagnostic : Défaillance cardiaque.
- sang : Défaillance cardiaque, Lymphoedème, Marqueurs biologiques, Peptide natriurétique cérébral.
- étiologie : Défaillance cardiaque.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Lymphoedème, Mâle.
English descriptors
- KwdEn :
- MESH :
- chemical , blood : Biomarkers, Natriuretic Peptide, Brain.
- blood : Heart Failure, Lymphedema.
- complications : Lymphedema.
- diagnosis : Heart Failure.
- etiology : Heart Failure.
- Adult, Female, Humans, Male, Middle Aged.
Abstract
Lymphedema often responds to compression therapy which can also cause undesirable cardiac overload if heart failure coexists. We hypothesized that the biomarker B-type natriuretic peptide (BNP) can be used to screen lymphedema patients for undetected cardiac dysfunction. We studied unselected consecutive patients with lymphedema to determine their BNP status and compared these data with those obtained from healthy subjects without known cardiovascular diseases. Out of a total of 305 subjects with lymphedema screened, 102 (33%) consented to take part in this study. The majority (87%) were female with a mean age of 60.5 +/- 13.2 (SD) years, and 47% had just lower limb swelling. The groups were equally divided between cancer and non-cancer related causes. There were 45 females and 4 males under 60 years old, and 44 female and 9 male patients over 60 years old. Median (IQR) BNP (ng/L) were as follows: <60 years females = 17.9 (15.2) (median [RR: 3 - 64] and males = 12.4 (14.7) [RR: 0.2 - 44], >60 years females = 35.8 (57.9) [RR: 2 -247)] and males = 47.2 (44.1) [RR: 2 - 238]. For this population, the BNP concentration 100 ng/L was adopted as the value to exclude heart failure. Using this definition, 7 lymphedema subjects had BNP concentrations of 120 (19.8) ng/L, and all were found to have cardiac abnormalities on echocardiography. This study demonstrated that 93% of unselected subjects with lymphedema had BNP concentrations that exclude a diagnosis of heart failure. Those subjects with elevated BNP were found on subsequent echocardiography to have cardiac abnormalities. The use of a BNP assay is of potential value in screening patients who are more likely to have cardiac failure. Indicative factors include bilateral leg swelling, over the age of 50 years, breathlessness, where there is no known cause for the swelling. A BNP assay using a BNP concentration threshold of 100 ng/L (29 pmol/L) will identify those patients who require more detailed investigations.
PubMed: 21667820
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:21667820Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">B-type natriuretic peptide in lymphedema.</title>
<author><name sortKey="Todd, J" sort="Todd, J" uniqKey="Todd J" first="J" last="Todd">J. Todd</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Lymphoedema, Leeds Teaching Hospitals NHS Trust, Leeds. Jacquelyne.Todd@leedsth.nhs.uk</nlm:affiliation>
<country wicri:rule="url">Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Austwick, T" sort="Austwick, T" uniqKey="Austwick T" first="T" last="Austwick">T. Austwick</name>
</author>
<author><name sortKey="Berridge, D" sort="Berridge, D" uniqKey="Berridge D" first="D" last="Berridge">D. Berridge</name>
</author>
<author><name sortKey="Tan, L B" sort="Tan, L B" uniqKey="Tan L" first="L B" last="Tan">L B Tan</name>
</author>
<author><name sortKey="Barth, J H" sort="Barth, J H" uniqKey="Barth J" first="J H" last="Barth">J H Barth</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2011">2011</date>
<idno type="RBID">pubmed:21667820</idno>
<idno type="pmid">21667820</idno>
<idno type="wicri:Area/PubMed/Corpus">002587</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002587</idno>
<idno type="wicri:Area/PubMed/Curation">002587</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002587</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002587</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002587</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">B-type natriuretic peptide in lymphedema.</title>
<author><name sortKey="Todd, J" sort="Todd, J" uniqKey="Todd J" first="J" last="Todd">J. Todd</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Lymphoedema, Leeds Teaching Hospitals NHS Trust, Leeds. Jacquelyne.Todd@leedsth.nhs.uk</nlm:affiliation>
<country wicri:rule="url">Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Austwick, T" sort="Austwick, T" uniqKey="Austwick T" first="T" last="Austwick">T. Austwick</name>
</author>
<author><name sortKey="Berridge, D" sort="Berridge, D" uniqKey="Berridge D" first="D" last="Berridge">D. Berridge</name>
</author>
<author><name sortKey="Tan, L B" sort="Tan, L B" uniqKey="Tan L" first="L B" last="Tan">L B Tan</name>
</author>
<author><name sortKey="Barth, J H" sort="Barth, J H" uniqKey="Barth J" first="J H" last="Barth">J H Barth</name>
</author>
</analytic>
<series><title level="j">Lymphology</title>
<idno type="ISSN">0024-7766</idno>
<imprint><date when="2011" type="published">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Biomarkers (blood)</term>
<term>Female</term>
<term>Heart Failure (blood)</term>
<term>Heart Failure (diagnosis)</term>
<term>Heart Failure (etiology)</term>
<term>Humans</term>
<term>Lymphedema (blood)</term>
<term>Lymphedema (complications)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Natriuretic Peptide, Brain (blood)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Défaillance cardiaque (diagnostic)</term>
<term>Défaillance cardiaque (sang)</term>
<term>Défaillance cardiaque (étiologie)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Lymphoedème ()</term>
<term>Lymphoedème (sang)</term>
<term>Marqueurs biologiques (sang)</term>
<term>Mâle</term>
<term>Peptide natriurétique cérébral (sang)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers</term>
<term>Natriuretic Peptide, Brain</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Heart Failure</term>
<term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Heart Failure</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Défaillance cardiaque</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Heart Failure</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Défaillance cardiaque</term>
<term>Lymphoedème</term>
<term>Marqueurs biologiques</term>
<term>Peptide natriurétique cérébral</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Défaillance cardiaque</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Femelle</term>
<term>Humains</term>
<term>Lymphoedème</term>
<term>Mâle</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Lymphedema often responds to compression therapy which can also cause undesirable cardiac overload if heart failure coexists. We hypothesized that the biomarker B-type natriuretic peptide (BNP) can be used to screen lymphedema patients for undetected cardiac dysfunction. We studied unselected consecutive patients with lymphedema to determine their BNP status and compared these data with those obtained from healthy subjects without known cardiovascular diseases. Out of a total of 305 subjects with lymphedema screened, 102 (33%) consented to take part in this study. The majority (87%) were female with a mean age of 60.5 +/- 13.2 (SD) years, and 47% had just lower limb swelling. The groups were equally divided between cancer and non-cancer related causes. There were 45 females and 4 males under 60 years old, and 44 female and 9 male patients over 60 years old. Median (IQR) BNP (ng/L) were as follows: <60 years females = 17.9 (15.2) (median [RR: 3 - 64] and males = 12.4 (14.7) [RR: 0.2 - 44], >60 years females = 35.8 (57.9) [RR: 2 -247)] and males = 47.2 (44.1) [RR: 2 - 238]. For this population, the BNP concentration 100 ng/L was adopted as the value to exclude heart failure. Using this definition, 7 lymphedema subjects had BNP concentrations of 120 (19.8) ng/L, and all were found to have cardiac abnormalities on echocardiography. This study demonstrated that 93% of unselected subjects with lymphedema had BNP concentrations that exclude a diagnosis of heart failure. Those subjects with elevated BNP were found on subsequent echocardiography to have cardiac abnormalities. The use of a BNP assay is of potential value in screening patients who are more likely to have cardiac failure. Indicative factors include bilateral leg swelling, over the age of 50 years, breathlessness, where there is no known cause for the swelling. A BNP assay using a BNP concentration threshold of 100 ng/L (29 pmol/L) will identify those patients who require more detailed investigations.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21667820</PMID>
<DateCreated><Year>2011</Year>
<Month>06</Month>
<Day>14</Day>
</DateCreated>
<DateCompleted><Year>2011</Year>
<Month>06</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0024-7766</ISSN>
<JournalIssue CitedMedium="Print"><Volume>44</Volume>
<Issue>1</Issue>
<PubDate><Year>2011</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Lymphology</Title>
<ISOAbbreviation>Lymphology</ISOAbbreviation>
</Journal>
<ArticleTitle>B-type natriuretic peptide in lymphedema.</ArticleTitle>
<Pagination><MedlinePgn>29-34</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Lymphedema often responds to compression therapy which can also cause undesirable cardiac overload if heart failure coexists. We hypothesized that the biomarker B-type natriuretic peptide (BNP) can be used to screen lymphedema patients for undetected cardiac dysfunction. We studied unselected consecutive patients with lymphedema to determine their BNP status and compared these data with those obtained from healthy subjects without known cardiovascular diseases. Out of a total of 305 subjects with lymphedema screened, 102 (33%) consented to take part in this study. The majority (87%) were female with a mean age of 60.5 +/- 13.2 (SD) years, and 47% had just lower limb swelling. The groups were equally divided between cancer and non-cancer related causes. There were 45 females and 4 males under 60 years old, and 44 female and 9 male patients over 60 years old. Median (IQR) BNP (ng/L) were as follows: <60 years females = 17.9 (15.2) (median [RR: 3 - 64] and males = 12.4 (14.7) [RR: 0.2 - 44], >60 years females = 35.8 (57.9) [RR: 2 -247)] and males = 47.2 (44.1) [RR: 2 - 238]. For this population, the BNP concentration 100 ng/L was adopted as the value to exclude heart failure. Using this definition, 7 lymphedema subjects had BNP concentrations of 120 (19.8) ng/L, and all were found to have cardiac abnormalities on echocardiography. This study demonstrated that 93% of unselected subjects with lymphedema had BNP concentrations that exclude a diagnosis of heart failure. Those subjects with elevated BNP were found on subsequent echocardiography to have cardiac abnormalities. The use of a BNP assay is of potential value in screening patients who are more likely to have cardiac failure. Indicative factors include bilateral leg swelling, over the age of 50 years, breathlessness, where there is no known cause for the swelling. A BNP assay using a BNP concentration threshold of 100 ng/L (29 pmol/L) will identify those patients who require more detailed investigations.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Todd</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Lymphoedema, Leeds Teaching Hospitals NHS Trust, Leeds. Jacquelyne.Todd@leedsth.nhs.uk</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Austwick</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Berridge</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Tan</LastName>
<ForeName>L B</ForeName>
<Initials>LB</Initials>
</Author>
<Author ValidYN="Y"><LastName>Barth</LastName>
<ForeName>J H</ForeName>
<Initials>JH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Lymphology</MedlineTA>
<NlmUniqueID>0155112</NlmUniqueID>
<ISSNLinking>0024-7766</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>114471-18-0</RegistryNumber>
<NameOfSubstance UI="D020097">Natriuretic Peptide, Brain</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020097" MajorTopicYN="N">Natriuretic Peptide, Brain</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year>
<Month>6</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2011</Year>
<Month>6</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2011</Year>
<Month>6</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">21667820</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
</list>
<tree><noCountry><name sortKey="Austwick, T" sort="Austwick, T" uniqKey="Austwick T" first="T" last="Austwick">T. Austwick</name>
<name sortKey="Barth, J H" sort="Barth, J H" uniqKey="Barth J" first="J H" last="Barth">J H Barth</name>
<name sortKey="Berridge, D" sort="Berridge, D" uniqKey="Berridge D" first="D" last="Berridge">D. Berridge</name>
<name sortKey="Tan, L B" sort="Tan, L B" uniqKey="Tan L" first="L B" last="Tan">L B Tan</name>
</noCountry>
<country name="Royaume-Uni"><noRegion><name sortKey="Todd, J" sort="Todd, J" uniqKey="Todd J" first="J" last="Todd">J. Todd</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002571 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002571 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:21667820 |texte= B-type natriuretic peptide in lymphedema. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:21667820" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
This area was generated with Dilib version V0.6.31. |